Risk stratification in cardiomyopathy.
CPET
Cardiomyopathy
MECKY score
exercise
prognosis
risk stratification
Journal
European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
12
1
2021
Statut:
ppublish
Résumé
Prognostic stratification of cardiomyopathies represents a cornerstone for the appropriate management of patients and is focused mainly on arrhythmic events and heart failure. Cardiopulmonary exercise testing provides additional prognostic information, particularly in the setting of heart failure. Cardiopulmonary exercise testing data, integrated in scores such as the Metabolism Exercise Cardiac Kidney Index score have been shown to improve the risk stratification of these patients. Cardiopulmonary exercise testing has been analysed as a potential supplier of prognostic parameters in the context of hypertrophic cardiomyopathy, for which it has been shown that a reduced oxygen consumption peak, an increased ventilation/carbon dioxide production slope and chronotropic incompetence correlate with a worse prognosis. To a lesser extent, in dilated cardiomyopathy, it has been shown that the percentage of oxygen consumption peak, not the pure value, and the ventilation/carbon dioxide production slope are associated with a greater cardiovascular risk. Few data are available about other cardiomyopathies (arrhythmogenic and restrictive). Cardiomyopathy patients should be early and routinely referred to heart failure advanced centres in order to perform a comprehensive risk stratification which should include a cardiopulmonary exercise test, with variables and cut-offs shown to improve their risk stratification.
Identifiants
pubmed: 33238741
doi: 10.1177/2047487320961898
pmc: PMC7691630
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-58Références
JACC Heart Fail. 2018 Aug;6(8):665-675
pubmed: 29803552
Int J Cardiol. 2018 Nov 15;271:125-131
pubmed: 30087038
Eur Heart J. 2008 Jan;29(2):270-6
pubmed: 17916581
Eur J Heart Fail. 2019 May;21(5):553-576
pubmed: 30989768
J Am Coll Cardiol. 2019 May 14;73(18):2328-2344
pubmed: 31072578
Ann Am Thorac Soc. 2017 Jul;14(Supplement_1):S102-S109
pubmed: 28375659
JACC Heart Fail. 2016 Aug;4(8):625-35
pubmed: 27179828
Circ Res. 2017 Sep 15;121(7):819-837
pubmed: 28912185
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Arq Bras Cardiol. 2017 Dec;109(6):533-540
pubmed: 29364349
Heart. 2016 Apr;102(8):602-9
pubmed: 26849900
ESC Heart Fail. 2017 Aug;4(3):341-350
pubmed: 28772037
Eur J Prev Cardiol. 2018 May;25(8):889-895
pubmed: 29569494
Circ Res. 2017 Sep 15;121(7):784-802
pubmed: 28912183
J Am Coll Cardiol. 1996 Feb;27(2):345-52
pubmed: 8557904
J Am Heart Assoc. 2020 Feb 4;9(3):e013695
pubmed: 32009524
Am J Cardiol. 2000 Jul 15;86(2):162-8
pubmed: 10913477
JACC Heart Fail. 2015 May;3(5):408-418
pubmed: 25863972
Ann Noninvasive Electrocardiol. 2016 May;21(3):263-71
pubmed: 26833673
Eur J Prev Cardiol. 2018 Dec;25(18):1937-1946
pubmed: 30247068
World J Cardiol. 2014 Dec 26;6(12):1234-44
pubmed: 25548613
Heart. 1998 Jul;80(1):60-7
pubmed: 9764062
Eur J Prev Cardiol. 2018 Mar;25(4):392-394
pubmed: 29243505
Circ Heart Fail. 2015 Nov;8(6):1022-31
pubmed: 26374874
Int J Cardiol. 2016 Nov 15;223:596-603
pubmed: 27561166
Am Heart J. 2015 May;169(5):684-692.e1
pubmed: 25965716
Int J Cardiol. 2016 Jan 15;203:1067-72
pubmed: 26638056
J Am Coll Cardiol. 2018 May 22;71(20):2293-2302
pubmed: 29773157